Home > > > > > Report Detail

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018

Publisher Name :
Date: 21-Sep-2018
No. of pages: 175

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for depression and anxiety disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD) and depression, and features dormant and discontinued products.

PTSD is a mental health condition that is triggered by either experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants and cognitive therapy. There are 38 products in development for this indication.

OCD is characterized by unreasonable thoughts and fears (obsessions) that lead to repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Treatment includes antidepressants and psychiatric medications. There are nine products in development for this indication.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers and antipsychotics. There are 212 products in development for this indication.

Molecular targets acted on by products in development for depression and anxiety disorders include neurotransmitter receptors such as glutamate receptors and 5-hydroxytryptamine receptors. Companies operating in this pipeline space include NeuroRx, Amorsa Therapeutics and Johnson & Johnson.

Scope

- Which companies are the most active within each pipeline?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Depression and Anxiety Disorders Report Coverage 9
2.2 Post-Traumatic Stress Disorder (PTSD) - Overview 9
2.3 Obsessive-Compulsive Disorder - Overview 9
2.4 Depression - Overview 9
3 Therapeutics Development 10
3.1 Post-Traumatic Stress Disorder (PTSD) 10
3.2 Obsessive-Compulsive Disorder 17
3.3 Depression 20
4 Therapeutics Assessment 41
4.1 Post-Traumatic Stress Disorder (PTSD) 41
4.2 Obsessive-Compulsive Disorder 49
4.3 Depression 54
5 Companies Involved in Therapeutics Development 68
5.1 Post-Traumatic Stress Disorder (PTSD) 68
5.2 Obsessive-Compulsive Disorder 78
5.3 Depression 80
6 Dormant Projects 122
6.1 Post-Traumatic Stress Disorder (PTSD) 122
6.2 Obsessive-Compulsive Disorder 124
6.3 Depression 125
7 Discontinued Products 141
7.1 Post-Traumatic Stress Disorder (PTSD) 141
7.2 Obsessive-Compulsive Disorder 141
7.3 Depression 142
8 Product Development Milestones 147
8.1 Post-Traumatic Stress Disorder (PTSD) 147
8.2 Obsessive-Compulsive Disorder 156
8.3 Depression 157
9 Appendix 174
9.1 Methodology 174
9.2 Coverage 174
9.3 Secondary Research 174
9.4 Primary Research 174
9.5 Expert Panel Validation 174
9.6 Contact Us 175
9.7 Disclaimer 175

1.1 List of Tables
Table 1: Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) 10
Table 2: Number of Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD) 12
Table 3: Number of Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD) 13
Table 4: Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD) 14
Table 5: Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD) 16
Table 6: Number of Products under Development for Obsessive-Compulsive Disorder 17
Table 7: Number of Products under Development by Companies, Obsessive-Compulsive Disorder 18
Table 8: Number of Products under Development by Universities/Institutes, Obsessive-Compulsive Disorder 19
Table 9: Products under Development by Companies, Obsessive-Compulsive Disorder 19
Table 10: Products under Development by Universities/Institutes, Obsessive-Compulsive Disorder 19
Table 11: Number of Products under Development for Depression 20
Table 12: Number of Products under Development by Companies, Depression 22
Table 13: Number of Products under Development by Universities/Institutes, Depression 27
Table 14: Products under Development by Companies, Depression 28
Table 15: Products under Development by Universities/Institutes, Depression 39
Table 16: Number of Products by Stage and Target, Post-Traumatic Stress Disorder (PTSD) 42
Table 17: Number of Products by Stage and Mechanism of Action, Post-Traumatic Stress Disorder (PTSD) 45
Table 18: Number of Products by Stage and Route of Administration, Post-Traumatic Stress Disorder (PTSD) 47
Table 19: Number of Products by Stage and Molecule Type, Post-Traumatic Stress Disorder (PTSD) 49
Table 20: Number of Products by Stage and Target, Obsessive-Compulsive Disorder 50
Table 21: Number of Products by Stage and Mechanism of Action, Obsessive-Compulsive Disorder 52
Table 22: Number of Products by Stage and Route of Administration, Obsessive-Compulsive Disorder 53
Table 23: Number of Products by Stage and Molecule Type, Obsessive-Compulsive Disorder 53
Table 24: Number of Products by Stage and Target, Depression 55
Table 25: Number of Products by Stage and Mechanism of Action, Depression 60
Table 26: Number of Products by Stage and Route of Administration, Depression 65
Table 27: Number of Products by Stage and Molecule Type, Depression 67
Table 28: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd 68
Table 29: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd 69
Table 30: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc 69
Table 31: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc 69
Table 32: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc 70
Table 33: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd 70
Table 34: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc 71
Table 35: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd 71
Table 36: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc 72
Table 37: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co 72
Table 38: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc 73
Table 39: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd 73
Table 40: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson 74
Table 41: Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc 74
Table 42: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp 75
Table 43: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd 76
Table 44: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics SAS 76
Table 45: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi 76
Table 46: Post-Traumatic Stress Disorder (PTSD) - Pipeline by SpringWorks Therapeutics LLC 77
Table 47: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp 77
Table 48: Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd 78
Table 49: Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc 78
Table 50: Obsessive-Compulsive Disorder - Pipeline by Biohaven Pharmaceutical Holding Company Ltd 79
Table 51: Obsessive-Compulsive Disorder - Pipeline by Omeros Corp 79

1.2 List of Figures
Figure 1: Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) 10
Figure 2: Number of Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD) 11
Figure 3: Number of Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD) 13
Figure 4: Number of Products under Development for Obsessive-Compulsive Disorder 17
Figure 5: Number of Products under Development by Companies, Obsessive-Compulsive Disorder 18
Figure 6: Number of Products under Development for Depression 20
Figure 7: Number of Products under Development by Companies, Depression 21
Figure 8: Number of Products under Development by Universities/Institutes, Depression 26
Figure 9: Number of Products by Top 10 Targets, Post-Traumatic Stress Disorder (PTSD) 41
Figure 10: Number of Products by Stage and Top 10 Targets, Post-Traumatic Stress Disorder (PTSD) 41
Figure 11: Number of Products by Top 10 Mechanism of Actions, Post-Traumatic Stress Disorder (PTSD) 43
Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions, Post-Traumatic Stress Disorder (PTSD) 44
Figure 13: Number of Products by Routes of Administration, Post-Traumatic Stress Disorder (PTSD) 46
Figure 14: Number of Products by Stage and Routes of Administration, Post-Traumatic Stress Disorder (PTSD) 47
Figure 15: Number of Products by Molecule Types, Post-Traumatic Stress Disorder (PTSD) 48
Figure 16: Number of Products by Stage and Molecule Types, Post-Traumatic Stress Disorder (PTSD) 48
Figure 17: Number of Products by Top 10 Targets, Obsessive-Compulsive Disorder 49
Figure 18: Number of Products by Stage and Top 10 Targets, Obsessive-Compulsive Disorder 50
Figure 19: Number of Products by Top 10 Mechanism of Actions, Obsessive-Compulsive Disorder 51
Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, Obsessive-Compulsive Disorder 51
Figure 21: Number of Products by Stage and Routes of Administration, Obsessive-Compulsive Disorder 52
Figure 22: Number of Products by Stage and Top 10 Molecule Types, Obsessive-Compulsive Disorder 53
Figure 23: Number of Products by Top 10 Targets, Depression 54
Figure 24: Number of Products by Stage and Top 10 Targets, Depression 54
Figure 25: Number of Products by Top 10 Mechanism of Actions, Depression 59
Figure 26: Number of Products by Stage and Top 10 Mechanism of Actions, Depression 59
Figure 27: Number of Products by Routes of Administration, Depression 64
Figure 28: Number of Products by Stage and Routes of Administration, Depression 65
Figure 29: Number of Products by Molecule Types, Depression 66
Figure 30: Number of Products by Stage and Molecule Types, Depression 66
  • Central Nervous System Disorder Drugs Industry Forecasts - China Focus
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 116
    This study focuses on China's Central Nervous System Disorder Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of g......
  • Central Nervous System Disorder Drugs Companies in China
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 48
    This study focuses on China's Central Nervous System Disorder Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market fo......
  • Central Nervous System Disorder Drugs Markets in China
    Published: 27-Nov-2023        Price: US 4000 Onwards        Pages: 214
    China's demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, in......
  • Global Drugs of Nervous System Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 14-Nov-2023        Price: US 3380 Onwards        Pages: 108
    Market Overview of Global Drugs of Nervous System market: According to our latest research, the global Drugs of Nervous System market looks promising in the next 5 years. As of 2022, the global Drugs of Nervous System market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, ......
  • Central Nervous System Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 650
    Central Nervous System Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the central nervous system deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of central nervous system deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal te......
  • Global Drugs of Nervous System Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 24-Feb-2023        Price: US 3260 Onwards        Pages: 123
    Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, Parkinson's disease, Alzheimer's disease, depression, anxiety and bipolar disorders. Epilepsy is a chronic brain disorder characterized by recurring seizures. Parkinson's disease is a degenerative CNS disorder associated with symptoms including tremor, rigidity, akinesia and bradykinesia. The Drugs of Nervous System market revenue was XX Million USD in 2022, and will r......
  • Global Drugs of Nervous System Market Research Report 2022 - Market Size, Current Insights and Development Trends
    Published: 26-Jan-2023        Price: US 3450 Onwards        Pages: 111
    Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, Parkinson's disease, Alzheimer's disease, depression, anxiety and bipolar disorders. Epilepsy is a chronic brain disorder characterized by recurring seizures. Parkinson's disease is a degenerative CNS disorder associated with symptoms including tremor, rigidity, akinesia and bradykinesia. The report focuses on the Drugs of Nervous System market size, segment si......
  • Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 30-Nov-2022        Price: US 2000 Onwards        Pages: 71
    Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Drugs In Development, 2022, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape. Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures......
  • Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 30-Nov-2022        Price: US 2000 Onwards        Pages: 40
    Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy (MLD) - Drugs In Development, 2022, provides an overview of the Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline landscape. Metachromatic leukodystrophy is an inherited disorder characterized ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs